LTRN News and Press, Lantern Pharma Inc. From 01/17/24

Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starl...

2023-12-13 08:05:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence ( AI ) industry have multiplie...

The Orphan Drug Designation strengthens LP-284’s clinical development path and can provide for additional market exclusivity and commercial protection. Lantern has initiated a first-in-human Phase 1 trial (NCT06132503) for LP-284 in B-cell non-Hodgkin’s lymphomas (NHL), incl...

2023-11-09 12:48:14 ET Gainers: Intelligent Bio Solutions ( INBS ) +149% . Pineapple Financial ( PAPL ) +87% . Ramaco Resources ( METC ) +34% . Tempest Therapeutics ( TPST ) +30% . Fitell Corp ( FTEL ) +32% . Honest Company (...

2023-11-09 05:28:04 ET Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Conference Call November 08, 2023 04:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants ...

2023-11-08 16:03:05 ET More on Lantern Pharma Seeking Alpha’s Quant Rating on Lantern Pharma Historical earnings data for Lantern Pharma Financial information for Lantern Pharma For further details see: Lantern Pharma GAAP EPS of -$0.29

Received IND clearance from FDA to initiate Phase 1 clinical trial for LP-284 , a first-in-human trial for advanced, refractory non-Hodgkin’s lymphomas (NHL). Dosed initial patient in Phase 1 with LP-184 , a clinical trial for multiple advanced solid tumors that are refractory ...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Lantern Pharma Inc. (LTRN) is expected to report $-0.46 for Q3 2023

Webcast to be held Wednesday, November 8th, 4:30 p.m. ET, register for the webcast here , or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN ), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its...